Evolution of systemic therapy for advanced pancreatic cancer.
about
Cancer of the Pancreas: Molecular Pathways and Current Advancement in TreatmentTargeting Epithelial-Mesenchymal Transition for Identification of Inhibitors for Pancreatic Cancer Cell Invasion and Tumor Spheres FormationPotential effects of Mina53 on tumor growth in human pancreatic cancerResveratrol inhibits the epithelial-mesenchymal transition of pancreatic cancer cells via suppression of the PI-3K/Akt/NF-κB pathwayEvaluation of a UCMK/dCK fusion enzyme for gemcitabine-mediated cytotoxicity.Pharmacologic ascorbate synergizes with gemcitabine in preclinical models of pancreatic cancerOncocytic-type intraductal papillary mucinous neoplasm (IPMN)-derived invasive oncocytic pancreatic carcinoma with brain metastasis - a case report.Prolonged complete response following gemcitabine-erlotinib combined therapy in advanced pancreatic cancerScreening for genes and subnetworks associated with pancreatic cancer based on the gene expression profileVitamin d and pancreatic cancer-an update.Current state of surgical management of pancreatic cancer.Autophagy and enhanced chemosensitivity in experimental pancreatic cancers induced by noninvasive radiofrequency field treatment.FOLFIRINOX for advanced pancreatic cancer: the Princess Margaret Cancer Centre experience.Antitumor Activities of Rauwolfia vomitoria Extract and Potentiation of Gemcitabine Effects Against Pancreatic Cancer.Activation of glucagon-like peptide-1 receptor inhibits tumourigenicity and metastasis of human pancreatic cancer cells via PI3K/Akt pathway.What's new in treatment of pancreatic cancer: a patent review (2010-2017).High Dose Parenteral Ascorbate Inhibited Pancreatic Cancer Growth and Metastasis: Mechanisms and a Phase I/IIa study.Pancreatic cancer and supportive care--pancreatic exocrine insufficiency negatively impacts on quality of life.Treatment of pancreatic cancer with intravenous vitamin C: a case report.Inhibition of pancreatic cancer stem cells by Rauwolfia vomitoria extractA phase II study of the halichondrin B analog eribulin mesylate in gemcitabine refractory advanced pancreatic cancer
P2860
Q26740619-66E335C1-FEEE-4153-A3A1-4B7FD8063455Q28552789-3710246B-98BE-4E92-8E7F-6F5BA699BF5BQ33755366-3B17A2CE-1E40-4693-AF84-D8E476F15372Q33857806-FA454B66-E6A8-4DEF-97ED-A37669C3924FQ35613655-480BB1D7-F8E2-4268-B3DA-1F857EF7A538Q36351453-09E43413-1751-4584-B2A5-AAEE0633A67BQ36369793-17B93DDC-8832-40AB-BFCF-6D108ECFFBA2Q36524171-747E648A-8F11-43A7-9ACF-5C824A5209FBQ36817494-63BDAC8C-2D8E-4A8B-8BCE-3A0F535FF332Q37129757-FC09D4E3-6258-411B-9D93-61DFA0A96CFEQ37129872-019498B1-202E-42F0-9534-E11CFC97DF9BQ37564404-ECFF4026-3C08-4D39-9CC2-3EF6216E382FQ38910968-C9EE40D5-A3DF-4180-99C1-A59B61813AFEQ39001305-EB5ED02B-3783-4A45-B12A-6C6656328AB4Q39014390-2CE0B6AC-768B-4048-A2B9-AA86470E5CDCQ39406815-9D07A5AE-4BFE-4382-8235-8433E903B4B6Q47112954-05ECFBCB-A686-4907-9C34-20745C4400B7Q48301649-8AAF4073-CDB3-48A8-AC1C-83303F841AEFQ50042500-FC72583E-C020-4CA6-A6A3-EA7957170DC8Q57074008-53DA968F-A545-42F5-82BF-BCE196C78B98Q58819336-43244BF9-3C22-49CF-88EF-F5D418950A6A
P2860
Evolution of systemic therapy for advanced pancreatic cancer.
description
2010 nî lūn-bûn
@nan
2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Evolution of systemic therapy for advanced pancreatic cancer.
@ast
Evolution of systemic therapy for advanced pancreatic cancer.
@en
Evolution of systemic therapy for advanced pancreatic cancer.
@nl
type
label
Evolution of systemic therapy for advanced pancreatic cancer.
@ast
Evolution of systemic therapy for advanced pancreatic cancer.
@en
Evolution of systemic therapy for advanced pancreatic cancer.
@nl
prefLabel
Evolution of systemic therapy for advanced pancreatic cancer.
@ast
Evolution of systemic therapy for advanced pancreatic cancer.
@en
Evolution of systemic therapy for advanced pancreatic cancer.
@nl
P2860
P356
P1476
Evolution of systemic therapy for advanced pancreatic cancer.
@en
P2093
Daniel Renouf
Malcolm Moore
P2860
P304
P356
10.1586/ERA.10.21
P577
2010-04-01T00:00:00Z